ScanScor WCFF Events
Total Events
5037
Fish Alarms
2006
Chart Now
2406
UP / DOWN / UNCERTAIN
684 / 1190 / 3163
Max Repricing
99%
Max Fade Risk
99%
| Created | Ticker | Direction | Alarm | Type | Risk | Headline | Reason |
|---|---|---|---|---|---|---|---|
|
2026-09-04 14:01:56
Story: 2026-09-04 10:01:00
|
ADIL
ID 5037
|
UNCERTAIN
Up 1% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 2% Fade: 95% Thesis Break: 0%
Today:
6.50 -
6.80
|
Retread Tires Market to Reach USD 18.503 Billion by 2035 says Radial Insights
Parse: PARSED
|
This is unrelated third-party tire market research, not an Adial biotech catalyst or company-specific development.
Input: ADEQUATE -
News-context mismatch is clear enough to classify as non-actionable noise.
|
|
2026-09-04 13:29:06
Story: 2026-09-04 09:28:00
|
PHGE
ID 5036
|
UNCERTAIN
Up 28% /
Down 22%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 31% Fade: 88% Thesis Break: 82%
Today:
0.13 -
0.17
|
BiomX: Zorronet Launches No-Code Control Over AI-Powered Autonomous Response Workflows
Parse: PARSED
|
Product-feature launch lacks revenue, contract, regulatory, or financing substance and is unlikely to drive durable repricing.
Input: ADEQUATE -
News and company context are sufficient; this appears promotional amid severe financial fragility and recent financing overhang.
|
|
2026-09-04 13:25:09
Story: 2026-09-04 09:19:08
|
PLRZ
ID 5035
|
DOWN
Up 12% /
Down 82%
|
Fish: YES
Chart: YES
HIGH
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 86% Fade: 71% Thesis Break: 63%
Today:
10.80 -
12.80
|
PLRZ SEC filing points to financing activity
Parse: PARSED
|
Registered direct plus private placement with warrants is concrete dilution news and usually pressures thin microcap biotech shares immediately.
Input: ADEQUATE -
Recent company PR already disclosed the offering, but this filing confirms material financing terms and dilution structure.
|
|
2026-09-04 13:10:09
Story: 2026-09-04 08:58:00
|
CLGN
ID 5034
|
UNCERTAIN
Up 28% /
Down 34%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
OTHER
ScanScor Filing Bot
|
Reprice: 41% Fade: 86% Thesis Break: 72%
Today:
2.95 -
3.75
|
CLGN files foreign issuer report with market-relevant terms
Parse: PARSED
|
This 6-K mainly formalizes a previously announced acquisition-related board appointment, so relevance exists but fresh standalone catalyst strength looks limited.
Input: ADEQUATE -
Recent acquisition, financing, reverse split, and compliance context is sufficient to judge this as noisy but monitor-worthy microcap news.
|
|
2026-09-04 13:05:40
Story: 2026-09-04 09:05:00
|
GPCR
ID 5033
|
UNCERTAIN
Up 4% /
Down 3%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 5% Fade: 85% Thesis Break: 1%
Today:
46.70 -
48.20
|
Sterling to Participate in Upcoming Investor Conferences
Parse: PARSED
|
Investor conference participation is routine, non-catalytic, and even appears mismatched to GPCR, so immediate repricing risk is minimal.
Input: ADEQUATE -
Story is sufficient to classify as routine and likely irrelevant to GPCR price action.
|
|
2026-09-04 13:02:12
Story: 2026-09-04 09:00:00
|
CBIO
ID 5032
|
UNCERTAIN
Up 2% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 3% Fade: 5% Thesis Break: 1%
Today:
20.20 -
21.30
|
Crescent Promotes Kristee Mitchell to Chief Supply Chain Officer
Parse: PARSED
|
This is unrelated executive promotion news from a different Crescent company and should not materially reprice CBIO.
Input: ADEQUATE -
The headline and body clearly indicate a non-biotech company, making this a ticker-news mismatch with negligible catalyst value.
|
|
2026-09-04 13:00:10
Story: 2026-09-04 08:51:33
|
XRTX
ID 5031
|
UNCERTAIN
Up 20% /
Down 45%
|
Fish: NO
Chart: YES
MEDIUM
|
WATCH_CHART
FINANCING
ScanScor Filing Bot
|
Reprice: 38% Fade: 82% Thesis Break: 68%
Today:
2.05 -
2.65
|
XRTX SEC filing points to financing activity
Parse: PARSED
|
Filing looks mostly like IR re-engagement and prior offering cleanup, with dilution overhang but limited evidence of a fresh financing catalyst.
Input: ADEQUATE -
Recent related filings show this may be recycled disclosure rather than a new capital raise.
|
|
2026-09-04 12:45:07
Story: 2026-09-04 08:30:14
|
EVGN
ID 5030
|
UNCERTAIN
Up 28% /
Down 34%
|
Fish: NO
Chart: NO
MEDIUM
|
ROUTINE_NEWS
OTHER
ScanScor Filing Bot
|
Reprice: 39% Fade: 82% Thesis Break: 58%
Today:
0.50 -
0.62
|
EVGN files foreign issuer report with market-relevant terms
Parse: PARSED
|
Rule-based 6-K alert lacks disclosed material details, so immediate repricing edge is weak despite microcap sensitivity.
Input: NEED_MORE_FILINGS -
Need the actual 6-K contents or exhibits to judge whether this is truly regulatory, financing, or boilerplate.
|
|
2026-09-04 12:43:09
Story: 2026-09-04 08:38:00
|
TARS
ID 5029
|
UNCERTAIN
Up 28% /
Down 22%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 24% Fade: 72% Thesis Break: 12%
Today:
81.00 -
86.00
|
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
Parse: PARSED
|
Acquisition closing was previously announced, and added Phase 3 asset has distant 2029 topline data, limiting immediate repricing impact.
Input: ADEQUATE -
News context clearly shows this is a transaction close, not a new catalyst or unexpected regulatory or clinical event.
|
|
2026-09-04 12:35:09
Story: 2026-09-04 08:30:05
|
QNCX
ID 5028
|
DOWN
Up 8% /
Down 72%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
COMPLIANCE
ScanScor Filing Bot
|
Reprice: 61% Fade: 44% Thesis Break: 68%
Today:
26.00 -
31.50
|
QNCX files 8-K with regulatory language
Parse: PARSED
|
8-K discloses Nasdaq equity noncompliance and possible delisting risk, a concrete negative catalyst for a tiny, fragile biotech.
Input: ADEQUATE -
Filing excerpt clearly identifies Item 3.01 Nasdaq noncompliance; no additional filing context is required for immediate reaction assessment.
|
|
2026-09-04 12:05:07
Story: 2026-09-04 08:00:18
|
PLUR
ID 5027
|
DOWN
Up 8% /
Down 78%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 72% Fade: 61% Thesis Break: 74%
Today:
1.18 -
1.42
|
PLUR SEC filing points to financing activity
Parse: PARSED
|
Form D tied to a concurrent registered direct and warrants reinforces recent dilution overhang for a weak microcap.
Input: ADEQUATE -
Recent offering context is sufficient; exact pricing terms from the underlying filing would improve precision.
|
|
2026-09-04 12:03:02
Story: 2026-09-04 08:00:00
|
NAUT
ID 5026
|
UNCERTAIN
Up 38% /
Down 14%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
OTHER
GlobeNewswire RSS
|
Reprice: 34% Fade: 78% Thesis Break: 12%
Today:
0.88 -
1.08
|
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
Parse: PARSED
|
Nature Methods validation is scientifically positive, but it is not revenue, regulatory, or commercial-launch news and likely drives only speculative attention.
Input: ADEQUATE -
Story context and company setup are sufficient; publication impact is assessable despite limited near-term commercialization detail.
|
|
2026-09-04 12:02:55
Story: 2026-09-04 08:00:00
|
URGN
ID 5025
|
UNCERTAIN
Up 8% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 5%
Today:
44.20 -
45.80
|
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement RSU grant for new hires is non-catalytic and unlikely to materially reprice a $2.2B biotech.
Input: ADEQUATE -
News is clear and recent context confirms this is a repeated administrative grant announcement, not a business catalyst.
|
|
2026-09-04 12:02:49
Story: 2026-09-04 08:00:00
|
RNTX
ID 5024
|
UNCERTAIN
Up 24% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 28% Fade: 82% Thesis Break: 8%
Today:
0.80 -
0.95
|
Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
Parse: PARSED
|
Conference poster notice references already published data, so it lacks fresh clinical catalyst power despite late-breaking framing.
Input: ADEQUATE -
News clearly states the poster data is already published, making immediate catalyst assessment straightforward.
|
|
2026-09-04 12:02:45
Story: 2026-09-04 08:00:00
|
ALMS
ID 5023
|
UNCERTAIN
Up 3% /
Down 4%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 6% Fade: 85% Thesis Break: 92%
Today:
10.70 -
11.80
|
Alumis to Participate in Upcoming September Investor Conferences
Parse: PARSED
|
Investor conference participation is routine and non-catalytic, especially after the recent lupus trial failure already drove the meaningful repricing.
Input: ADEQUATE -
News is clear and recent context strongly indicates this headline lacks standalone catalyst value.
|
|
2026-09-04 12:02:38
Story: 2026-09-04 08:00:00
|
IOVA
ID 5022
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 72% Thesis Break: 4%
Today:
8.45 -
8.95
|
Iovance Biotherapeutics to Present at Upcoming Conferences
Parse: PARSED
|
Conference presentation notice is routine IR news with no new data, deal, regulatory action, or financing catalyst.
Input: ADEQUATE -
Story content is sufficient to classify this as non-actionable routine conference participation.
|
|
2026-09-04 12:02:32
Story: 2026-09-04 08:00:00
|
TSHA
ID 5021
|
UNCERTAIN
Up 4% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
INSIDER
GlobeNewswire RSS
|
Reprice: 8% Fade: 85% Thesis Break: 2%
Today:
5.50 -
5.75
|
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement equity grant for new hires is non-catalytic and unlikely to materially reprice TSHA.
Input: ADEQUATE -
Story is clear and recent context confirms this is a repeated routine compensation disclosure, not a clinical or financing catalyst.
|
|
2026-09-04 12:02:27
Story: 2026-09-04 08:00:00
|
NTLA
ID 5020
|
UNCERTAIN
Up 6% /
Down 4%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 8% Fade: 85% Thesis Break: 3%
Today:
12.55 -
13.05
|
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Parse: PARSED
|
Conference presentation notice is routine and lacks new clinical, regulatory, financing, or partnership substance.
Input: ADEQUATE -
Story content is sufficient because it clearly contains no fresh catalyst beyond an investor conference appearance.
|
|
2026-09-04 12:01:19
Story: 2026-09-04 08:00:00
|
TYRA
ID 5019
|
UNCERTAIN
Up 38% /
Down 22%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
CLINICAL_DATA
PRNewswire RSS
|
Reprice: 41% Fade: 63% Thesis Break: 18%
Today:
22.90 -
25.80
|
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
Parse: PARSED
|
Data are not released yet, but scheduling initial Phase 2 results can create anticipatory volatility, especially with high short interest.
Input: ADEQUATE -
Enough context exists to assess near-term event reaction, though actual SURF302 efficacy and safety details remain unknown.
|
|
2026-09-04 11:33:26
Story: 2026-09-04 07:32:00
|
CMND
ID 5018
|
DOWN
Up 28% /
Down 72%
|
Fish: YES
Chart: YES
HIGH
|
STRAY_WILDCAT_DOWN
OTHER
GlobeNewswire RSS
|
Reprice: 79% Fade: 88% Thesis Break: 91%
Today:
1.55 -
2.60
|
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
Parse: PARSED
|
Biotech buying an unrelated EV charging asset signals strategy drift and likely credibility damage, despite possible low-float speculative spikes.
Input: ADEQUATE -
News, float, market cap, financing context, and prior LOI are sufficient to judge immediate reaction risk.
|
|
2026-09-04 11:31:01
Story: 2026-09-04 07:30:00
|
KURA
ID 5017
|
UNCERTAIN
Up 3% /
Down 7%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 8% Fade: 2% Thesis Break: 1%
Today:
12.95 -
13.30
|
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement option grants for new hires are non-catalytic and rarely drive meaningful repricing.
Input: ADEQUATE -
News item is clear and sufficient; no additional context is needed for this event-reaction assessment.
|
|
2026-09-04 11:07:41
Story: 2026-09-04 07:05:00
|
ZBIO
ID 5016
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 78% Thesis Break: 4%
Today:
31.90 -
33.40
|
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
Parse: PARSED
|
Investor conference presentation news is routine and lacks new clinical, regulatory, financing, or partnership substance.
Input: ADEQUATE -
Enough context is provided to classify this as non-actionable routine investor-relations news.
|
|
2026-09-04 11:05:08
Story: 2026-09-04 07:00:08
|
EVAX
ID 5015
|
DOWN
Up 12% /
Down 74%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 78% Fade: 58% Thesis Break: 41%
Today:
2.75 -
3.25
|
EVAX SEC filing points to financing activity
Parse: PARSED
|
6-K discloses recent ATM ADS sales, a concrete dilution signal for a tiny biotech already prone to financing-driven pressure.
Input: ADEQUATE -
Filing excerpts include a current ATM sale amount and timing, enough to assess near-term dilution reaction risk.
|
|
2026-09-04 11:02:05
Story: 2026-09-04 07:00:00
|
BSEM
ID 5014
|
UP
Up 63% /
Down 22%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
PARTNERSHIP
GlobeNewswire RSS
|
Reprice: 58% Fade: 71% Thesis Break: 46%
Today:
3.45 -
4.25
|
BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier
Parse: PARSED
|
First GPO contract coverage expands hospital ordering access, but revenue timing is unclear and microcap liquidity raises pop-and-fade risk.
Input: ADEQUATE -
News is fresh and concrete, but no contract economics or near-term sales guidance were disclosed.
|
|
2026-09-04 11:01:59
Story: 2026-09-04 07:00:00
|
BIOT
ID 5013
|
UNCERTAIN
Up 18% /
Down 22%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 16% Fade: 91% Thesis Break: 78%
Today:
0.37 -
0.46
|
INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives
Parse: PARSED
|
Operational update mostly repeats prior announcements without new contracts, financing, clinical data, or regulatory milestones.
Input: ADEQUATE -
Story and recent context are sufficient to judge this as low-novelty promotional update news.
|
|
2026-09-04 11:01:55
Story: 2026-09-04 07:00:00
|
VRXA
ID 5012
|
UNCERTAIN
Up 12% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 16% Fade: 78% Thesis Break: 10%
Today:
1.45 -
1.68
|
VERAXA Biotech Appoints Raju Willener as Chief Financial Officer
Parse: PARSED
|
CFO appointment is routine management news without clinical, regulatory, financing, or partnership substance to justify immediate repricing attention.
Input: ADEQUATE -
Story and context are sufficient; no concrete catalyst in the release suggests meaningful near-term price discovery.
|
|
2026-09-04 11:00:46
Story: 2026-09-04 07:00:00
|
INSM
ID 5011
|
UNCERTAIN
Up 3% /
Down 5%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 6% Fade: 2% Thesis Break: 1%
Today:
124.00 -
129.00
|
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine Nasdaq inducement grants for new hires are non-catalytic compensation disclosures and rarely drive meaningful biotech repricing.
Input: ADEQUATE -
News item is clear and sufficient; no additional filings or clinical context are needed for event-reaction assessment.
|
|
2026-09-04 10:10:14
Story: 2026-09-04 06:01:59
|
IONS
ID 5010
|
UNCERTAIN
Up 28% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
REGULATORY
ScanScor Filing Bot
|
Reprice: 22% Fade: 82% Thesis Break: 8%
Today:
57.20 -
60.50
|
IONS files 8-K with clinical-trial language
Parse: PARSED
|
8-K appears to formalize yesterday’s already public FDA approval, so incremental repricing value now is limited.
Input: ADEQUATE -
Recent headline context clearly shows the approval was disclosed yesterday, reducing novelty of this filing-triggered alert.
|
|
2026-09-04 10:10:08
Story: 2026-09-04 06:02:27
|
SNTI
ID 5009
|
DOWN
Up 12% /
Down 78%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 74% Fade: 71% Thesis Break: 83%
Today:
0.29 -
0.37
|
SNTI SEC filing points to financing activity
Parse: PARSED
|
Convertible note funding and merger-linked equity commitment signal dilution pressure for an already distressed microcap.
Input: ADEQUATE -
Filing excerpts show current financing terms and merger-linked equity issuance, enough for immediate event-reaction assessment.
|
|
2026-09-04 10:01:45
Story: 2026-09-04 06:00:00
|
IMRN
ID 5008
|
UP
Up 62% /
Down 24%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_UP
PARTNERSHIP
GlobeNewswire RSS
|
Reprice: 58% Fade: 78% Thesis Break: 66%
Today:
1.03 -
1.35
|
Immuron to launch PROIBS® in the United States
Parse: PARSED
|
U.S. launch/distribution deal adds near-term commercial narrative, but tiny cap and supplement-style product make any spike highly fade-prone.
Input: ADEQUATE -
News is fresh and concrete, but revenue economics of the distribution agreement are not disclosed.
|
|
2026-09-04 00:35:09
Story: 2026-09-03 20:30:04
|
VBIO
ID 5007
|
DOWN
Up 12% /
Down 74%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 63% Fade: 82% Thesis Break: 88%
Today:
2.35 -
3.15
|
VBIO SEC filing points to financing activity
Parse: PARSED
|
13D/A reinforces dilution-linked financing overhang after reverse split in a distressed microcap, creating immediate downside attention despite likely noisy trading.
Input: ADEQUATE -
Filing context, reverse split, ownership structure, and repeated financing signals are sufficient for a short-window event-reaction judgment.
|
|
2026-09-03 22:40:08
Story: 2026-09-03 18:23:53
|
PRTA
ID 5006
|
UP
Up 62% /
Down 18%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
INSIDER
ScanScor Filing Bot
|
Reprice: 54% Fade: 67% Thesis Break: 22%
Today:
9.35 -
9.95
|
PRTA insider purchase filing detected
Parse: PARSED
|
Repeated open-market buying by a 10% owner is supportive, but this is not new fundamental data and may only cause a modest, fade-prone repricing.
Input: ADEQUATE -
Form 4 details, prior insider pattern, short interest, and liquidity are sufficient for an event-reaction judgment.
|
|
2026-09-03 21:20:08
Story: 2026-09-03 17:05:38
|
IMVT
ID 5005
|
UNCERTAIN
Up 12% /
Down 18%
|
Fish: NO
Chart: NO
MEDIUM
|
ROUTINE_NEWS
OTHER
ScanScor Filing Bot
|
Reprice: 22% Fade: 72% Thesis Break: 14%
Today:
38.40 -
40.20
|
IMVT files 8-K with regulatory language
Parse: PARSED
|
Detected tags appear driven by boilerplate; visible 8-K content points to shareholder vote disclosure, not a clear fresh catalyst.
Input: NEED_MORE_FILINGS -
Need the actual 8-K item details and exhibits, because the provided excerpts are mostly boilerplate and may misclassify the event.
|
|
2026-09-03 21:16:18
Story: 2026-09-03 17:15:00
|
ACHV
ID 5004
|
UNCERTAIN
Up 4% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 6%
Today:
8.15 -
8.40
|
Achieve Life Sciences Announced Granting of New Hire Inducement Awards
Parse: PARSED
|
New-hire inducement awards are routine compensation news and do not change ACHV’s regulatory, financing, or clinical outlook.
Input: ADEQUATE -
Story details are sufficient because this is clearly a standard inducement grant announcement with no concrete catalyst.
|
|
2026-09-03 20:50:08
Story: 2026-09-03 16:39:01
|
MGNX
ID 5003
|
UNCERTAIN
Up 20% /
Down 35%
|
Fish: NO
Chart: NO
MEDIUM
|
ROUTINE_NEWS
FINANCING
ScanScor Filing Bot
|
Reprice: 28% Fade: 72% Thesis Break: 22%
Today:
4.05 -
4.38
|
MGNX SEC filing points to financing activity
Parse: PARSED
|
8-K/A appears tied to previously disclosed asset-sale financing details, not a clearly new dilutive capital raise catalyst.
Input: ADEQUATE -
Filing excerpts suggest amendment and pro forma sale accounting, but full filing review would confirm whether any new securities terms exist.
|
|
2026-09-03 20:34:17
Story: 2026-09-03 16:32:00
|
DBVT
ID 5002
|
UNCERTAIN
Up 6% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 78% Thesis Break: 4%
Today:
13.35 -
14.10
|
DBV Technologies to Participate in Upcoming September Investor Conferences
Parse: PARSED
|
Investor conference participation is routine and lacks new clinical, regulatory, financing, or partnership substance to justify immediate repricing attention.
Input: ADEQUATE -
Story is clear routine IR news with sufficient context to judge low catalyst value.
|
|
2026-09-03 20:31:56
Story: 2026-09-03 16:30:00
|
TNYA
ID 5001
|
UNCERTAIN
Up 6% /
Down 4%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 8% Fade: 85% Thesis Break: 3%
Today:
0.68 -
0.72
|
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
Parse: PARSED
|
Investor conference participation is routine and lacks new clinical, regulatory, financing, or partnership catalyst content.
Input: ADEQUATE -
News item is clear and recent context confirms this is a repeat-style investor relations announcement.
|
|
2026-09-03 20:31:50
Story: 2026-09-03 16:30:00
|
CLLS
ID 5000
|
UNCERTAIN
Up 3% /
Down 4%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 5% Fade: 2% Thesis Break: 1%
Today:
3.28 -
3.36
|
Monthly information on share capital and company voting rights
Parse: PARSED
|
Monthly share capital and voting-rights disclosure is routine administrative news with no fresh catalyst or clear valuation impact.
Input: ADEQUATE -
Story content and recent context are sufficient to classify this as non-actionable routine disclosure.
|
|
2026-09-03 20:15:07
Story: 2026-09-03 16:10:20
|
NXTC
ID 4999
|
DOWN
Up 12% /
Down 74%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 71% Fade: 63% Thesis Break: 68%
Today:
6.70 -
8.10
|
NXTC SEC filing points to financing activity
Parse: PARSED
|
Fresh 8-K financing/offering signals likely imply dilution or overhang for a small-cap biotech already prone to volatile repricing.
Input: NEED_MORE_FILINGS -
Need the actual 8-K terms, size, pricing, and warrant details to confirm dilution severity and timing.
|
|
2026-09-03 20:10:12
Story: 2026-09-03 16:01:03
|
BYSI
ID 4998
|
DOWN
Up 12% /
Down 68%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 54% Fade: 71% Thesis Break: 63%
Today:
0.56 -
0.68
|
BYSI SEC filing points to financing activity
Parse: PARSED
|
Possible financing and dilution signals in a weak sub-$1 biotech can pressure shares immediately, though proxy-based filing evidence is noisy.
Input: NEED_MORE_FILINGS -
Need the full DEF 14A details to confirm whether financing is current, approved, or merely referenced boilerplate.
|
|
2026-09-03 20:10:07
Story: 2026-09-03 16:03:53
|
GOSS
ID 4997
|
DOWN
Up 12% /
Down 68%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 41% Fade: 72% Thesis Break: 58%
Today:
0.16 -
0.19
|
GOSS SEC filing points to financing activity
Parse: PARSED
|
PRE 14A supports previously announced dilutive private placement and Nasdaq approval needs, creating renewed downside attention but likely not a fresh thesis-changing shock.
Input: ADEQUATE -
News is actionable enough because filing confirms financing mechanics, but much of the core transaction was already disclosed on August 21.
|
|
2026-09-03 20:09:18
Story: 2026-09-03 16:08:00
|
VANI
ID 4996
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 4%
Today:
1.36 -
1.45
|
Vivani Medical Announces Participation in Upcoming Investor Conferences
Parse: PARSED
|
Investor conference participation is routine and lacks new clinical, regulatory, financing, or partnership substance likely to reprice shares immediately.
Input: ADEQUATE -
Story is clear routine IR news with sufficient market and company context to judge low immediate catalyst value.
|
|
2026-09-03 20:08:05
Story: 2026-09-03 16:05:00
|
AGMB
ID 4995
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 82% Thesis Break: 2%
Today:
14.20 -
15.10
|
Agomab to Participate in Upcoming Investor Conferences
Parse: PARSED
|
Investor conference participation is routine IR news with no clinical, regulatory, financing, or partnership catalyst.
Input: ADEQUATE -
Story content is clear and sufficient to classify as non-actionable routine news.
|
|
2026-09-03 20:08:00
Story: 2026-09-03 16:05:00
|
SPRO
ID 4994
|
UNCERTAIN
Up 3% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 6% Fade: 92% Thesis Break: 4%
Today:
1.18 -
1.24
|
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement equity grant for new employees is non-catalytic and rarely drives meaningful biotech repricing.
Input: ADEQUATE -
News is clear and recent context confirms this is a repeated administrative grant announcement.
|
|
2026-09-03 20:07:54
Story: 2026-09-03 16:05:00
|
KTTA
ID 4993
|
UNCERTAIN
Up 8% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 88% Thesis Break: 6%
Today:
0.56 -
0.61
|
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
Parse: PARSED
|
Investor conference participation is routine, non-catalytic news and usually does not justify immediate biotech repricing attention.
Input: ADEQUATE -
Story is clear and recent, but it contains no new data, regulatory action, financing, or partnership catalyst.
|
|
2026-09-03 20:07:49
Story: 2026-09-03 16:05:00
|
TNGX
ID 4992
|
UNCERTAIN
Up 4% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 6% Fade: 2% Thesis Break: 1%
Today:
22.20 -
23.10
|
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Nasdaq inducement grant news is routine compensation disclosure and lacks clinical, regulatory, financing, or partnership catalyst value.
Input: ADEQUATE -
Story content is sufficient because inducement grant disclosures are typically non-catalytic and low market relevance.
|
|
2026-09-03 20:07:44
Story: 2026-09-03 16:05:00
|
CNTB
ID 4991
|
UNCERTAIN
Up 8% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 5%
Today:
1.85 -
2.02
|
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Parse: PARSED
|
Conference presentation notice is routine IR news without new data, financing, partnership, or regulatory catalyst.
Input: ADEQUATE -
Story is clear and recent context confirms upcoming September topline data matters more than this conference appearance.
|
|
2026-09-03 20:07:38
Story: 2026-09-03 16:05:00
|
IMRX
ID 4990
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 78% Thesis Break: 4%
Today:
4.95 -
5.15
|
Immuneering to Participate in Upcoming Investor Conferences
Parse: PARSED
|
Investor conference participation is routine IR news without new data, financing, partnership, or regulatory catalyst.
Input: ADEQUATE -
Story is clear and recent, but it lacks any concrete catalyst likely to drive immediate repricing.
|
|
2026-09-03 20:07:33
Story: 2026-09-03 16:05:00
|
PCVX
ID 4989
|
UP
Up 62% /
Down 18%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
OTHER
GlobeNewswire RSS
|
Reprice: 58% Fade: 41% Thesis Break: 14%
Today:
60.20 -
63.80
|
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Parse: PARSED
|
Narrowed Phase 3 topline timing to end-October modestly de-risks execution and can lift sentiment, but no actual data were released.
Input: ADEQUATE -
News is fresh and specific, with enough catalyst context to assess near-term reaction risk.
|
|
2026-09-03 20:07:27
Story: 2026-09-03 16:05:00
|
WVE
ID 4988
|
UNCERTAIN
Up 6% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 9% Fade: 78% Thesis Break: 4%
Today:
4.62 -
4.82
|
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
Parse: PARSED
|
Conference presentation notice lacks new data, regulatory action, financing, or partnership catalyst and is unlikely to drive meaningful repricing.
Input: ADEQUATE -
Story is clear and recent, but it is routine investor-conference news without a concrete catalyst.
|
|
2026-09-03 20:06:16
Story: 2026-09-03 16:05:00
|
ELVN
ID 4987
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 10% Fade: 72% Thesis Break: 4%
Today:
58.40 -
60.80
|
Enliven Therapeutics to Present at Upcoming Investor Conferences
Parse: PARSED
|
Investor conference participation is routine and lacks new clinical, regulatory, financing, or partnership substance to drive immediate repricing.
Input: ADEQUATE -
News item is clear and sufficient because it contains no concrete catalyst beyond standard investor outreach.
|
|
2026-09-03 20:06:07
Story: 2026-09-03 16:05:00
|
BSEM
ID 4986
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 78% Thesis Break: 5%
Today:
3.48 -
3.78
|
BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Parse: PARSED
|
Conference presentation notice is routine, recently repeated, and lacks new clinical, regulatory, financing, or partnership substance.
Input: ADEQUATE -
News and context are sufficient to classify this as low-urgency routine investor-conference publicity.
|
|
2026-09-03 20:06:02
Story: 2026-09-03 16:05:00
|
SYRE
ID 4985
|
UNCERTAIN
Up 6% /
Down 4%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 8% Fade: 85% Thesis Break: 3%
Today:
86.00 -
88.50
|
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
Parse: PARSED
|
Investor conference participation is routine IR news with no new clinical, regulatory, financing, or partnership catalyst.
Input: ADEQUATE -
Story is clear and recent context confirms no embedded catalyst beyond standard conference appearances.
|
|
2026-09-03 20:05:56
Story: 2026-09-03 16:05:00
|
LTGO
ID 4984
|
UNCERTAIN
Up 28% /
Down 22%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
EARNINGS
GlobeNewswire RSS
|
Reprice: 24% Fade: 72% Thesis Break: 18%
Today:
21.90 -
23.20
|
Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Parse: PARSED
|
Mostly routine earnings-style recap with previously known IPO, publication, and runway updates, lacking a fresh discrete catalyst.
Input: ADEQUATE -
Story provides enough context to judge it as low-urgency routine news without immediate catalyst-driven repricing pressure.
|
|
2026-09-03 20:02:30
Story: 2026-09-03 16:01:00
|
ARVN
ID 4983
|
UNCERTAIN
Up 6% /
Down 5%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 8% Fade: 82% Thesis Break: 3%
Today:
9.15 -
9.45
|
Arvinas to Participate in Upcoming Investor Conferences
Parse: PARSED
|
Investor conference participation is routine IR news with no disclosed clinical, regulatory, financing, or partnership catalyst.
Input: ADEQUATE -
News item is clear and sufficient to classify as non-actionable routine conference participation.
|
|
2026-09-03 20:02:25
Story: 2026-09-03 16:01:00
|
XENE
ID 4982
|
UNCERTAIN
Up 6% /
Down 5%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 8% Fade: 78% Thesis Break: 2%
Today:
59.70 -
61.20
|
Xenon to Present at Wells Fargo Healthcare Conference
Parse: PARSED
|
Investor conference presentation notice lacks new data, guidance, deal terms, or regulatory catalyst and is usually non-actionable routine IR news.
Input: ADEQUATE -
Story content is sufficient because it clearly indicates a standard conference appearance without a concrete catalyst.
|
|
2026-09-03 20:02:19
Story: 2026-09-03 16:01:00
|
PRAX
ID 4981
|
UNCERTAIN
Up 2% /
Down 4%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 5% Fade: 85% Thesis Break: 1%
Today:
349.00 -
358.00
|
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement equity grant filing for new hires is non-catalytic and unlikely to change valuation or near-term thesis.
Input: ADEQUATE -
Story is clear and sufficient; no additional filings or clinical context are needed for this event-reaction assessment.
|
|
2026-09-03 20:02:14
Story: 2026-09-03 16:01:00
|
NAMS
ID 4980
|
UNCERTAIN
Up 3% /
Down 7%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
INSIDER
GlobeNewswire RSS
|
Reprice: 8% Fade: 85% Thesis Break: 2%
Today:
25.40 -
26.10
|
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement equity grants for new hires are non-catalytic and unlikely to drive meaningful repricing in a $3B biotech.
Input: ADEQUATE -
News is clear and repetitive, with enough market context to classify as low-urgency routine compensation disclosure.
|
|
2026-09-03 20:02:08
Story: 2026-09-03 16:01:00
|
RNTX
ID 4979
|
UNCERTAIN
Up 12% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 78% Thesis Break: 6%
Today:
0.80 -
0.88
|
Rein Therapeutics to Present at Upcoming September Investor Conferences
Parse: PARSED
|
Investor conference presentation news is routine and lacks new clinical, regulatory, financing, or partnership catalyst content.
Input: ADEQUATE -
Story and context are sufficient to classify this as non-actionable routine investor relations news.
|
|
2026-09-03 18:33:49
Story: 2026-09-03 14:32:00
|
APLT
ID 4978
|
UNCERTAIN
Up 28% /
Down 12%
|
Fish: NO
Chart: YES
MEDIUM
|
WATCH_CHART
PRECLINICAL
GlobeNewswire RSS
|
Reprice: 24% Fade: 88% Thesis Break: 10%
Today:
0.09 -
0.14
|
Applied Biologics Achieves Key Preclinical Milestone in Disease-Modifying Osteoarthritis Gene Therapy Program
Parse: PARSED
|
Very early preclinical vector-function update may spark a microcap pop, but lacks human data, financing impact, or regulatory substance.
Input: NEED_MORE_FILINGS -
Ticker-company identity appears mismatched, and current share price/volume data are stale for sizing immediate repricing risk.
|
|
2026-09-03 16:15:09
Story: 2026-09-03 12:03:12
|
ALP
ID 4977
|
DOWN
Up 12% /
Down 78%
|
Fish: YES
Chart: YES
HIGH
|
STRAY_WILDCAT_DOWN
COMPLIANCE
ScanScor Filing Bot
|
Reprice: 74% Fade: 71% Thesis Break: 83%
Today:
0.13 -
0.17
|
ALP files foreign issuer report with market-relevant terms
Parse: PARSED
|
1-for-50 reverse split to maintain Nasdaq compliance is typically bearish for distressed microcaps and raises near-term dilution and fade concerns.
Input: ADEQUATE -
Filing excerpts clearly describe a current reverse split compliance event, which is sufficient for immediate event-reaction assessment.
|
|
2026-09-03 15:50:14
Story: 2026-09-03 11:43:42
|
CANF
ID 4976
|
DOWN
Up 12% /
Down 74%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 68% Fade: 79% Thesis Break: 71%
Today:
2.18 -
2.55
|
CANF SEC filing points to financing activity
Parse: PARSED
|
Fresh financing-related 6-K after warrant exercise suggests near-term dilution overhang for a tiny, weak microcap despite possible runway extension.
Input: ADEQUATE -
Signal is actionable, but filing excerpts may include boilerplate and should be confirmed against the full 6-K terms.
|
|
2026-09-03 15:50:09
Story: 2026-09-03 11:45:15
|
GTBP
ID 4975
|
DOWN
Up 12% /
Down 78%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
COMPLIANCE
ScanScor Filing Bot
|
Reprice: 74% Fade: 67% Thesis Break: 71%
Today:
0.25 -
0.30
|
GTBP SEC filing points to financing activity
Parse: PARSED
|
Reverse split and Nasdaq-compliance style filing on a distressed microcap usually signals dilution risk and near-term downside repricing.
Input: ADEQUATE -
Filing excerpts clearly indicate a current reverse split event despite noisy rule tags.
|
|
2026-09-03 14:16:19
Story: 2026-09-03 10:15:00
|
SLS
ID 4974
|
DOWN
Up 8% /
Down 72%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
OTHER
PRNewswire RSS
|
Reprice: 58% Fade: 67% Thesis Break: 74%
Today:
12.80 -
14.60
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS
Parse: PARSED
|
Law-firm investigation amplifies existing trial-result delay concerns and can pressure sentiment, though these alerts often create noisy, fade-prone downside.
Input: ADEQUATE -
Need company response or actual REGAL data timing to refine whether this remains headline noise or deepens into a larger repricing.
|
|
2026-09-03 14:16:10
Story: 2026-09-03 10:15:00
|
LENZ
ID 4973
|
DOWN
Up 8% /
Down 42%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 18% Fade: 72% Thesis Break: 64%
Today:
5.45 -
5.95
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ
Parse: PARSED
|
Law firm investigation alerts usually echo prior bad news and rarely create fresh standalone biotech repricing catalysts.
Input: ADEQUATE -
Story is clear and references already digested earnings and downgrade-driven weakness rather than new operational disclosures.
|
|
2026-09-03 14:16:03
Story: 2026-09-03 10:15:00
|
EYPT
ID 4972
|
UNCERTAIN
Up 5% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 8% Fade: 95% Thesis Break: 92%
Today:
4.55 -
4.95
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Parse: PARSED
|
Law firm investigation alert is recycled post-drop headline noise, not a new operational catalyst for EyePoint.
Input: ADEQUATE -
Recent failed Phase 3 context and prior identical law firm alerts make this non-actionable for fresh repricing.
|
|
2026-09-03 14:15:58
Story: 2026-09-03 10:15:00
|
SION
ID 4971
|
UNCERTAIN
Up 8% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 92% Thesis Break: 98%
Today:
6.50 -
7.60
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION
Parse: PARSED
|
Repeat law-firm investigation notice after the August clinical collapse adds little new information and is unlikely to drive fresh durable repricing.
Input: ADEQUATE -
Recent headline history clearly shows this is recycled shareholder-lawyer noise, not a new operating catalyst.
|
|
2026-09-03 14:15:52
Story: 2026-09-03 10:15:00
|
ABEO
ID 4970
|
DOWN
Up 5% /
Down 28%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 18% Fade: 82% Thesis Break: 22%
Today:
5.72 -
6.02
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
Parse: PARSED
|
Law firm investigation alert is recycled, non-fundamental headline and usually creates little new repricing after the original earnings-driven drop.
Input: ADEQUATE -
Recent duplicate Pomerantz alert and underlying August 13 catalyst are already in context, making this event easy to classify.
|
|
2026-09-03 14:01:49
Story: 2026-09-03 10:00:00
|
REGN
ID 4969
|
DOWN
Up 2% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 6% Fade: 95% Thesis Break: 4%
Today:
838.00 -
851.00
|
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN
Parse: PARSED
|
Repeat class-action reminder tied to months-old disclosed events, with little new information and low odds of fresh institutional repricing.
Input: ADEQUATE -
News context clearly shows repeated lawsuit alerts, making this low-signal and non-catalytic for immediate price discovery.
|
|
2026-09-03 14:01:43
Story: 2026-09-03 10:01:00
|
ADIL
ID 4968
|
UNCERTAIN
Up 1% /
Down 1%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 1% Fade: 99% Thesis Break: 0%
Today:
6.20 -
6.45
|
Solid Tire Market to Reach USD 729.02 Million by 2035 - Radial Insights
Parse: PARSED
|
Third-party tire market report is unrelated to Adial Pharmaceuticals and provides no company-specific biotech catalyst.
Input: ADEQUATE -
Story is clearly irrelevant to ADIL, so no additional filings or clinical context are needed.
|
|
2026-09-03 14:01:36
Story: 2026-09-03 10:00:00
|
SPRY
ID 4967
|
DOWN
Up 3% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 8% Fade: 85% Thesis Break: 10%
Today:
5.70 -
5.95
|
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY
Parse: PARSED
|
Repeat class-action reminder tied to already-known June coverage miss, with little new information and limited incremental repricing power.
Input: ADEQUATE -
Recent headline history clearly shows this is repetitive legal-advertisement noise rather than a fresh operating catalyst.
|
|
2026-09-03 14:01:26
Story: 2026-09-03 10:00:00
|
GUTS
ID 4966
|
DOWN
Up 3% /
Down 18%
|
Fish: NO
Chart: NO
HIGH
|
IGNORE
OTHER
PRNewswire RSS
|
Reprice: 12% Fade: 92% Thesis Break: 8%
Today:
0.66 -
0.72
|
Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers - GUTS
Parse: PARSED
|
Routine plaintiff-law-firm class action notice repeats old January damage and rarely creates fresh biotech repricing by itself.
Input: ADEQUATE -
Recent context shows this same lawsuit theme already circulated, limiting incremental information value.
|
|
2026-09-03 14:01:05
Story: 2026-09-03 10:00:00
|
AARD
ID 4965
|
DOWN
Up 3% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 8% Fade: 92% Thesis Break: 88%
Today:
5.65 -
6.05
|
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors - AARD
Parse: PARSED
|
Class-action filing is recycled plaintiff-lawyer news after the core clinical-hold damage was already disclosed months ago.
Input: ADEQUATE -
Recent headline history clearly shows repeated lawsuit notices, limiting incremental information value.
|
|
2026-09-03 13:36:17
Story: 2026-09-03 09:35:00
|
MIST
ID 4964
|
UP
Up 78% /
Down 22%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_UP
REGULATORY
GlobeNewswire RSS
|
Reprice: 81% Fade: 58% Thesis Break: 24%
Today:
1.18 -
1.45
|
Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States
Parse: PARSED
|
China approval validates ex-U.S. commercialization and adds milestone economics, but the $2M payment is modest so upside may be real yet fade-prone.
Input: ADEQUATE -
Fresh approval, licensing economics, market cap, short interest, and price context are sufficient for immediate event-reaction assessment.
|
|
2026-09-03 13:35:08
Story: 2026-09-03 09:28:09
|
CLGN
ID 4963
|
DOWN
Up 22% /
Down 74%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 71% Fade: 83% Thesis Break: 68%
Today:
0.28 -
0.39
|
CLGN SEC filing points to financing activity
Parse: PARSED
|
Closing an equity-heavy acquisition with warrants adds dilution risk for a tiny fragile microcap despite strategic narrative.
Input: ADEQUATE -
Filing excerpts and recent transaction history are sufficient to flag immediate dilution-driven chart risk.
|
|
2026-09-03 13:30:12
Story: 2026-09-03 09:21:44
|
SMMT
ID 4962
|
DOWN
Up 18% /
Down 67%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 61% Fade: 58% Thesis Break: 24%
Today:
14.35 -
15.95
|
SMMT SEC filing points to financing activity
Parse: PARSED
|
Possible financing or offering language creates near-term dilution overhang, but filing excerpts look partly boilerplate and not thesis-breaking.
Input: NEED_MORE_FILINGS -
Need the actual 8-K item details and exhibits to confirm whether this is a new financing event or recycled disclosure.
|
|
2026-09-03 13:16:09
Story: 2026-09-03 09:15:00
|
LGVN
ID 4961
|
UNCERTAIN
Up 8% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 20%
Today:
6.70 -
7.35
|
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Parse: PARSED
|
Conference presentation notice is routine and lacks new clinical, regulatory, financing, or partnership catalyst to drive immediate repricing.
Input: ADEQUATE -
Story and context are sufficient; no fresh catalyst is disclosed beyond standard investor conference participation.
|
|
2026-09-03 13:01:03
Story: 2026-09-03 09:00:00
|
PALI
ID 4960
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 4%
Today:
1.96 -
2.12
|
Palisade Bio to Participate in Upcoming Investor Conferences
Parse: PARSED
|
Investor conference participation is routine, repeated IR news without new clinical, regulatory, financing, or partnership catalyst.
Input: ADEQUATE -
Enough context to judge this as non-actionable routine news with limited immediate repricing relevance.
|
|
2026-09-03 13:00:08
Story: 2026-09-03 08:53:40
|
APGE
ID 4959
|
UNCERTAIN
Up 8% /
Down 22%
|
Fish: NO
Chart: NO
MEDIUM
|
ROUTINE_NEWS
OTHER
ScanScor Filing Bot
|
Reprice: 18% Fade: 12% Thesis Break: 10%
Today:
133.50 -
135.50
|
APGE SEC filing points to financing activity
Parse: PARSED
|
Rule-based filing alert appears tied to previously disclosed AbbVie merger mechanics, not a clearly new dilutive financing catalyst.
Input: TOO_MUCH_NOISE -
Need the actual 8-K event summary because extracted tags conflict and likely misclassify merger-related boilerplate as financing.
|
|
2026-09-03 12:51:57
Story: 2026-09-03 08:50:00
|
PLRZ
ID 4958
|
DOWN
Up 12% /
Down 86%
|
Fish: YES
Chart: YES
HIGH
|
STRAY_WILDCAT_DOWN
FINANCING
GlobeNewswire RSS
|
Reprice: 91% Fade: 78% Thesis Break: 72%
Today:
9.00 -
11.20
|
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
Parse: PARSED
|
Discounted registered direct plus warrants is dilutive microcap financing that usually pressures price despite extending cash runway.
Input: ADEQUATE -
Offering terms, share count impact, market cap, float, and recent catalyst context are sufficient for event-reaction assessment.
|
|
2026-09-03 12:35:07
Story: 2026-09-03 08:30:12
|
JAGX
ID 4957
|
DOWN
Up 8% /
Down 82%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
FINANCING
ScanScor Filing Bot
|
Reprice: 76% Fade: 71% Thesis Break: 88%
Today:
0.58 -
0.76
|
JAGX files SEC registration or offering documents
Parse: PARSED
|
424B5 offering paperwork on a distressed microcap strongly signals dilution pressure and can trigger immediate downside repricing despite possible brief reflex bounces.
Input: ADEQUATE -
Enough context exists to classify this as actionable financing-related dilution risk, though exact terms from the filing were not extracted.
|
|
2026-09-03 12:33:40
Story: 2026-09-03 08:30:00
|
CRVS
ID 4956
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 12% Fade: 78% Thesis Break: 4%
Today:
13.90 -
14.55
|
Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference
Parse: PARSED
|
Conference presentation notice lacks new clinical, regulatory, financing, or partnership substance and usually does not drive durable repricing.
Input: ADEQUATE -
Story is clear and recent, and context shows this is a standard investor-conference announcement without fresh catalyst content.
|
|
2026-09-03 12:33:33
Story: 2026-09-03 08:30:00
|
ONCO
ID 4955
|
UNCERTAIN
Up 44% /
Down 28%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
PARTNERSHIP
GlobeNewswire RSS
|
Reprice: 58% Fade: 88% Thesis Break: 76%
Today:
0.61 -
0.82
|
Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events
Parse: PARSED
|
Realbotix pilot may spark speculative attention, but it is indirect, non-binding acquisition-target news on an extremely fragile microcap.
Input: ADEQUATE -
Enough context exists to judge this as speculative catalyst news with elevated fade risk and limited fundamental support.
|
|
2026-09-03 12:31:59
Story: 2026-09-03 08:30:00
|
KALA
ID 4954
|
UNCERTAIN
Up 58% /
Down 42%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
PARTNERSHIP
GlobeNewswire RSS
|
Reprice: 64% Fade: 88% Thesis Break: 79%
Today:
0.49 -
0.72
|
Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program
Parse: PARSED
|
Definitive agreement may spark another microcap squeeze, but it mostly formalizes a two-day-old LOI with no disclosed economics.
Input: ADEQUATE -
News, balance-sheet risk, prior LOI timing, and microcap trading context are sufficient for an event-reaction judgment.
|
|
2026-09-03 12:31:52
Story: 2026-09-03 08:30:00
|
BBLG
ID 4953
|
UNCERTAIN
Up 8% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 92% Thesis Break: 75%
Today:
0.52 -
0.60
|
Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Parse: PARSED
|
Conference participation without new data, financing, or regulatory catalyst is routine and unlikely to drive durable repricing.
Input: ADEQUATE -
Story is clear routine investor-conference news; recent financing context reinforces fade-prone microcap behavior.
|
|
2026-09-03 12:31:47
Story: 2026-09-03 08:30:00
|
BCAX
ID 4952
|
UNCERTAIN
Up 4% /
Down 8%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 9% Fade: 85% Thesis Break: 3%
Today:
23.00 -
24.10
|
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Parse: PARSED
|
Routine inducement option grants for new hires are non-catalytic and unlikely to drive meaningful repricing in a $1.56B biotech.
Input: ADEQUATE -
News item is clear and sufficient; no additional filings or clinical context are needed for this event-reaction assessment.
|
|
2026-09-03 12:30:40
Story: 2026-09-03 08:30:00
|
TLPH
ID 4951
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 10% Fade: 78% Thesis Break: 4%
Today:
1.16 -
1.24
|
Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Parse: PARSED
|
Conference participation is routine investor-relations news with no new clinical, regulatory, financing, or partnership catalyst.
Input: ADEQUATE -
Story and context are sufficient; no concrete catalyst is disclosed beyond a standard conference appearance.
|
|
2026-09-03 12:30:34
Story: 2026-09-03 08:30:00
|
CTXR
ID 4950
|
UNCERTAIN
Up 8% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
PRNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 20%
Today:
0.55 -
0.62
|
Citius Pharmaceuticals to Participate in September 2026 Investor Conferences
Parse: PARSED
|
Investor conference participation is routine and lacks new clinical, regulatory, financing, or partnership catalyst content.
Input: ADEQUATE -
Story is clear and recent, but it contains no concrete catalyst beyond management presentations.
|
|
2026-09-03 12:30:26
Story: 2026-09-03 08:30:00
|
FBLG
ID 4949
|
UNCERTAIN
Up 38% /
Down 22%
|
Fish: NO
Chart: YES
MEDIUM
|
WATCH_CHART
OTHER
PRNewswire RSS
|
Reprice: 34% Fade: 82% Thesis Break: 68%
Today:
1.78 -
2.35
|
FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing
Parse: PARSED
|
New patent may spark a microcap sympathy pop, but repeated patent PRs without clinical or commercial inflection usually fade quickly.
Input: ADEQUATE -
Recent similar patent headlines and microcap trading context are sufficient to judge this as low-quality catalyst news.
|
|
2026-09-03 12:25:07
Story: 2026-09-03 08:15:14
|
APVO
ID 4948
|
DOWN
Up 18% /
Down 62%
|
Fish: YES
Chart: YES
MEDIUM
|
STRAY_WILDCAT_DOWN
COMPLIANCE
ScanScor Filing Bot
|
Reprice: 54% Fade: 81% Thesis Break: 74%
Today:
1.85 -
2.45
|
APVO files 8-K with clinical-trial language
Parse: PARSED
|
8-K signal appears mixed and likely boilerplate-heavy, but Nasdaq compliance language on a distressed microcap can trigger downside repricing.
Input: NEED_MORE_FILINGS -
Need the actual 8-K item details because the extracted clinical and FDA terms may be boilerplate rather than a current catalyst.
|
|
2026-09-03 12:10:12
Story: 2026-09-03 08:00:31
|
LQDA
ID 4947
|
UP
Up 68% /
Down 18%
|
Fish: YES
Chart: YES
MEDIUM
|
WATCH_CHART
REGULATORY
ScanScor Filing Bot
|
Reprice: 61% Fade: 58% Thesis Break: 14%
Today:
68.00 -
74.00
|
LQDA files 8-K with clinical-trial language
Parse: PARSED
|
Fast Track designation is a real regulatory catalyst, but it supports an early Phase 2 program and may produce only a moderate, fade-prone uplift.
Input: ADEQUATE -
Filing excerpts clearly show a current FDA Fast Track event with planned Phase 2a timing, sufficient for immediate reaction assessment.
|
|
2026-09-03 12:10:07
Story: 2026-09-03 08:00:33
|
JUNS
ID 4946
|
UNCERTAIN
Up 18% /
Down 34%
|
Fish: NO
Chart: NO
MEDIUM
|
IGNORE
COMPLIANCE
ScanScor Filing Bot
|
Reprice: 29% Fade: 82% Thesis Break: 61%
Today:
2.95 -
3.95
|
JUNS files 8-K with regulatory language
Parse: PARSED
|
Detected regulatory language appears mostly boilerplate, with Item 5.03 suggesting charter/bylaw changes rather than a clear catalyst.
Input: NEED_MORE_FILINGS -
Need the actual 8-K substance and exhibits, because the scan excerpts do not confirm a material FDA or Nasdaq event.
|
|
2026-09-03 12:06:56
Story: 2026-09-03 08:04:00
|
SXTP
ID 4945
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 12%
Today:
0.90 -
1.05
|
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
Parse: PARSED
|
Conference participation and investor meetings are routine, non-catalytic disclosures with little standalone repricing power despite SXTP’s fragile microcap profile.
Input: ADEQUATE -
News is clear and recent context is sufficient to classify this as routine non-catalyst communication.
|
|
2026-09-03 12:06:51
Story: 2026-09-03 08:05:00
|
HRMY
ID 4944
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 12% Fade: 72% Thesis Break: 4%
Today:
42.20 -
43.60
|
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
Parse: PARSED
|
Encore poster presentation notice with no new clinical results, regulatory action, or financing catalyst is routine and unlikely to reprice shares.
Input: ADEQUATE -
Headline and body clearly indicate conference poster logistics rather than fresh catalyst-bearing data.
|
|
2026-09-03 12:03:28
Story: 2026-09-03 08:00:00
|
MENS
ID 4943
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 88% Thesis Break: 12%
Today:
2.15 -
2.35
|
Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow
Parse: PARSED
|
Investor roadshow participation is promotional routine news without clinical, regulatory, financing, or partnership substance.
Input: ADEQUATE -
News content is clear and sufficient to classify as low-urgency non-catalyst communication.
|
|
2026-09-03 12:03:23
Story: 2026-09-03 08:00:00
|
REPL
ID 4942
|
UNCERTAIN
Up 6% /
Down 4%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 8% Fade: 82% Thesis Break: 3%
Today:
15.40 -
16.20
|
Replimune to Present at the Cantor Global Healthcare Conference 2026
Parse: PARSED
|
Conference presentation notice is routine IR news with no new data, deal, regulatory action, or financing catalyst.
Input: ADEQUATE -
Story content is sufficient to classify this as non-actionable routine conference participation.
|
|
2026-09-03 12:03:17
Story: 2026-09-03 08:00:00
|
PRME
ID 4941
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 78% Thesis Break: 4%
Today:
3.55 -
3.82
|
Prime Medicine to Participate in Upcoming Investor Conferences
Parse: PARSED
|
Investor conference participation is routine and lacks new clinical, regulatory, financing, or partnership substance.
Input: ADEQUATE -
Story is clear and recent, but it contains no concrete catalyst beyond scheduled conference appearances.
|
|
2026-09-03 12:03:11
Story: 2026-09-03 08:00:00
|
NVCT
ID 4940
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 78% Thesis Break: 4%
Today:
23.10 -
24.60
|
Nuvectis Pharma To Participate in Upcoming Investor Conferences
Parse: PARSED
|
Investor conference participation is routine IR news with no new clinical, regulatory, financing, or partnership catalyst to drive immediate repricing.
Input: ADEQUATE -
Story is clear and recent context confirms this is non-catalytic conference participation rather than substantive business news.
|
|
2026-09-03 12:03:06
Story: 2026-09-03 08:00:00
|
BMEA
ID 4939
|
UNCERTAIN
Up 8% /
Down 6%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 78% Thesis Break: 4%
Today:
1.84 -
2.02
|
Biomea Fusion to Participate in Upcoming Investor Conferences
Parse: PARSED
|
Investor conference participation is routine and repeats prior patterns, with no new clinical, regulatory, financing, or partnership catalyst disclosed.
Input: ADEQUATE -
Enough context exists to classify this as non-actionable routine IR news despite nearby anticipated trial milestones.
|
|
2026-09-03 12:03:01
Story: 2026-09-03 08:00:00
|
CVKD
ID 4938
|
UNCERTAIN
Up 8% /
Down 12%
|
Fish: NO
Chart: NO
HIGH
|
ROUTINE_NEWS
OTHER
GlobeNewswire RSS
|
Reprice: 10% Fade: 85% Thesis Break: 18%
Today:
1.26 -
1.45
|
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Parse: PARSED
|
Conference participation is routine and repeats prior catalyst themes without new data, deal terms, regulatory action, or financing change.
Input: ADEQUATE -
Fresh headline is clear and recent context shows the real catalyst was the August FDA meeting update, not this conference notice.
|